IL2 and renal cell carcinoma: A retrospective observational cohort study examining the survival of patients with melanoma and stage 4 renal cell carcinoma linked the occurrence of irAEs after checkpoint inhibitor treatment and IL-2 as a positive prognostic factor for therapeutic response [13].